Reunion Neuroscience (TSX:REUN) Cash Flow from Others : C$1.89 Mil (TTM As of Mar. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Reunion Neuroscience Cash Flow from Others?

Reunion Neuroscience's cash flow from others for the three months ended in Mar. 2023 was C$-0.03 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Mar. 2023 was C$1.89 Mil.

Reunion Neuroscience Cash Flow from Others Historical Data

The historical data trend for Reunion Neuroscience's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reunion Neuroscience Cash Flow from Others Chart

Reunion Neuroscience Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Cash Flow from Others

0.02

1.93

0.04

1.89

Reunion Neuroscience Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Cash Flow from Others	Get a 7-Day Free Trial										0.73	-0.36	7.91	-5.64	-0.03

Reunion Neuroscience Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$1.89 Mil.

Reunion Neuroscience Cash Flow from Others Related Terms

Thank you for viewing the detailed overview of Reunion Neuroscience's Cash Flow from Others provided by GuruFocus.com. Please click on the following links to see related term pages.

Reunion Neuroscience (TSX:REUN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reunion Neuroscience Inc (TSX:REUN) » Definitions » Cash Flow from Others

Comparable Companies

Traded in Other Exchanges

N/A

Address

30 Duncan Street, Lower North Suite, Toronto, ON, CAN, M5V 2C3

Website

https://www.reunionneuro.com

Reunion Neuroscience Inc is engaged in novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company's asset, RE-104 (previously known as FT-104), is a proprietary, novel psychedelic drug being developed for post-partum and treatment-resistant depression as a potential fast-acting antidepressant with durable efficacy.